Silver Book Fact

Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.

Caro, Jaime, Denis Getsios, Kristen Migliaccio-Walle, Jack Ishak, and Wissam El-Hadi. Rational Choice of Cholinesterase Inhibitor for the Treatment of Alzheimer s Disease in Canada: A comparative economic analysis. BMC Geriatrics. 2003; 3(6). http://www.biomedcentral.com/1471-2318/3/6

Reference

Title
Rational Choice of Cholinesterase Inhibitor for the Treatment of Alzheimer s Disease in Canada: A comparative economic analysis
Publication
BMC Geriatrics
Publication Date
2003
Authors
Caro, Jaime, Denis Getsios, Kristen Migliaccio-Walle, Jack Ishak, and Wissam El-Hadi
Volume & Issue
Volume 3, Issue 6
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Stopping the Progress of Parkinson’s Would Save >$440,000 per Person
     
  • Stem Cell Therapy Study Shows Improved Motor Function in Parkinson’s
     
  • If the progression of Parkinson’s disease were slowed by 50%, there would be a 35% reduction in excess costs.  
  • According to the Pharmaceutical Research and Manufacturers of America, because of medical research, the number of Americans with Alzheimer’s could decrease by 3 million in 2025.  
  • According to the Pharmaceutical Research and Manufacturers of America, 42 medicines are currently in development for Alzheimer’s disease.